PITTSBURGH (BUSINESS WIRE) #CRS CytoAgents, Inc., a clinical-stage biotechnology company developing a safe, effective treatment for Cytokine Release Syndrome (CRS), today announced that it has initiated recruitment and will enroll its first patient at UPMC Hillman Cancer Center, in the Phase 1b/2a clinical trial.
/PRNewswire/ Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of.